Alps Advisors Inc. Decreases Holdings in Aadi Bioscience, Inc. (NASDAQ:AADI)

Alps Advisors Inc. decreased its position in shares of Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) by 42.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,423 shares of the company’s stock after selling 9,046 shares during the period. Alps Advisors Inc. owned 0.06% of Aadi Bioscience worth $153,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Royal Bank of Canada purchased a new stake in Aadi Bioscience during the first quarter valued at approximately $49,000. Strs Ohio purchased a new position in shares of Aadi Bioscience in the second quarter worth $41,000. JPMorgan Chase & Co. purchased a new position in shares of Aadi Bioscience in the second quarter worth $95,000. Neville Rodie & Shaw Inc. purchased a new position in shares of Aadi Bioscience in the second quarter worth $164,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Aadi Bioscience in the first quarter worth $294,000. Hedge funds and other institutional investors own 63.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH decreased their price target on shares of Aadi Bioscience to $47.00 in a report on Tuesday, November 15th.

Aadi Bioscience Price Performance

NASDAQ:AADI opened at $13.17 on Thursday. The firm has a market capitalization of $321.28 million, a P/E ratio of -4.42 and a beta of 1.28. Aadi Bioscience, Inc. has a 1-year low of $11.00 and a 1-year high of $26.60. The company’s fifty day moving average price is $13.11 and its 200-day moving average price is $13.35.

Aadi Bioscience Profile

(Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Featured Articles

Institutional Ownership by Quarter for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.